Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$105,000.00

Role of leukotriene receptor antagonists in the treatment and prevention of dementia and cardiovascular disease: a longitudinal study using Ontario health administrative data

FY 2021-22

Summary
Alzheimer's disease (AD) and cardiovascular disease (CVD) affect many elderly people and are among the top 10 leading causes of death among Canadians. AD affects the brain and causes dementia, a condition characterized by a progressive decline in a person's ability to think and function. CVD describes conditions which affect the heart and blood vessels such as heart attack and stroke. AD and CVD often occur together. It has been suggested that CVD may contribute to the development and progression of AD. Currently, there is no cure for AD, prompting the need to explore new treatment options. Leukotriene receptor antagonists (LTRAs) are a class of medications currently used to treat asthma. Recent studies suggest that LTRAs may be beneficial for AD and CVD. This research aims to determine if use of LTRAs is associated with a lower risk of AD- and CVD-related outcomes among people aged 65 and older living in Ontario. Outcomes which will be explored include dementia, stroke, heart attack, and entering a long-term care home. This study will also explore the extent to which CVD contributes to the development of dementia. This research could provide evidence to support a new treatment or prevention option for people at risk of AD and CVD, and therefore, may present the opportunity to reduce significant morbidity and mortality among elderly Canadians.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
458258
Name
Xiong Lisa
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
Role of leukotriene receptor antagonists in the treatment and prevention of dementia and cardiovascular disease: a longitudinal study using Ontario health administrative data
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Cardiovascular Disease; Cohort; Dementia; Leukotriene Receptor Antagonists; Longitudinal; Pharmacoepidemiology; Propensity Score Matching
Abstract
Alzheimer's disease (AD) and cardiovascular disease (CVD) affect many elderly people and are among the top 10 leading causes of death among Canadians. AD affects the brain and causes dementia, a condition characterized by a progressive decline in a person's ability to think and function. CVD describes conditions which affect the heart and blood vessels such as heart attack and stroke. AD and CVD often occur together. It has been suggested that CVD may contribute to the development and progression of AD. Currently, there is no cure for AD, prompting the need to explore new treatment options. Leukotriene receptor antagonists (LTRAs) are a class of medications currently used to treat asthma. Recent studies suggest that LTRAs may be beneficial for AD and CVD. This research aims to determine if use of LTRAs is associated with a lower risk of AD- and CVD-related outcomes among people aged 65 and older living in Ontario. Outcomes which will be explored include dementia, stroke, heart attack, and entering a long-term care home. This study will also explore the extent to which CVD contributes to the development of dementia. This research could provide evidence to support a new treatment or prevention option for people at risk of AD and CVD, and therefore, may present the opportunity to reduce significant morbidity and mortality among elderly Canadians.
Competitiondate
202111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Xiong, Lisa
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~